Abstract
The most common genetic alteration identified in transitional cell carcinoma (TCC) of the bladder is loss of heterozygosity (LOH) on chromosome 9. However, localization of tumor suppressor genes on 9q has been hampered by the low frequency of subchromosomal deletions. We have analysed 139 primary, initial low stage TCC of the bladder using a panel of 28 microsatellite markers spanning chromosome 9 at an average distance of 5 Mb, following a primer-extension preamplification (PEP) technique. Sixty-seven (48%) tumors showed LOH at one or more loci and partial deletions were detected in 62 (45%) tumors; apparent monosomy 9 was detected in only five (4%) tumors. Deletions were more frequent on 9q (44%) than on 9p (23%), the latter being mostly associated with 9q deletion, suggesting that alteration of genes on 9q may be an early event associated with superficial papillary tumors. Combined data from the cases with partial 9q deletions displayed four candidate regions for tumor suppressor loci, based on the frequency of deletion observed and tumors with unique deletions at these sites. In two tumors, the unique partial deletion comprised D9S12 at 9q22.3, a region encompassing loci for the Gorlin syndrome and multiple self-healing squamous epithelioma gene. In two other tumors, the single LOH was identified at the D9S172 locus at 9q31-32 where the dysautonia and Fukuyama-type congenital muscular dystrophy genes have been located. One tumor showed unique LOH at the GSN locus at 9q33, a region frequently deleted in other sporadic tumors while the fourth region of deletion was observed at 9q34 between ASS and ABL-1, in two tumors. This region is frequently deleted in tumors and encompasses the locus for the hereditary hemorrhagic telangiectasia gene. These findings suggest four target regions on 9q within which suppressor genes for TCC may reside.
This is a preview of subscription content, access via your institution
Access options
Similar content being viewed by others
References
Allard P, Fradet Y, Têtu B, Bernard P and the Québec Urology Research Group. . 1995 Clin. Cancer Res. 1: 1195–1202.
Cairns P, Shaw ME and Knowles MA. . 1993 Cancer Res. 53: 1230–1232.
Cairns P, Tokino K, Eby Y and Sidransky D. . 1994 Cancer Res. 54: 1422–1424.
Dalbagni G, Presti J, Reuter V, Fair WR and Cordon-Cardo C. . 1993 Lancet 342: 469–471.
Devlin J, Keen AJ and Knowles MA. . 1994 Oncogene 9: 2757–2760.
Diaz MO, Rubin CM, Harden A, Ziemen S, Larson RA, Le Beau MM and Rowley JD. . 1990 N. Engl. J. Med. 322: 77–82.
Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, Titus-Ernstoff L, Bouchard B, Vijayasaradhi S, Houghton AN, Lahti J, Kidd VJ, Housman DE and Dracopoli NC. . 1992 Proc. Natl. Acad. Sci. USA 89: 10557–10561.
Habuchi T, Devlin J, Elder PA and Knowles MA. . 1995 Oncogene 11: 1671–1674.
Habuchi T, Yoshida O and Knowles MA. . 1997 Hum. Mol. Genet. 6: 913–919.
Hornigold N, Van Slegtenhorst M, Nahmias J, Ekong R, Rousseaux S, Hermans C, Halley D, Povey S and Wolfe JA. . 1997 Genomics 41: 385–389.
Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RSl, Johnson BE and Skolnick MH. . 1994 Science 264: 436–440.
Keen AJ and Knowles MA. . 1994 Oncogene 9: 2083–2088.
Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME and Law MG. . 1994 Cancer Res. 54: 531–538.
LaRue H, Simoneau M and Fradet Y. . 1995 Clinical Cancer Res. 1: 435–440.
Linnenbach AJ, Pressler LB, Seng BA, Kimmel BS, Tomaszewski JE and Malkowicz SB. . 1993 Hum. Mol. Genet. 2: 1407–1411.
Marchuk DA, Papenberg KA, Jackson CE, Markel DS, Guttmacher AE and Greenspan DS. . 1994 Ann. Hum. Genet. 58: 224–225.
McDonald MT, Papenberg KA, Ghosh S, Glatfelter AA, Biesecker BB, Helmbold EA, Markel DS, Zolotor A, McKinnon WC, Vanderstoep JL, Jackson CE, Iannuzzi M, Collins FS, Boehnke M, Porteous ME, Guttmacher AE and Marchuk DA. . 1994 Nature Genet. 6: 197–204.
Meldgaard P, Johnson PH, Langkilde NC, Wolf H and Orntoft TF. . 1995 Int. J. Cancer 63: 341–344.
Merlo A, Gabrielson E, Mabry M, Vollmer R, Baylin SB and Sidransky D. . 1994 Cancer Res. 54: 2322–2326.
Miyake M, Nakahori Y, Matsushita I, Kobayashi K, Mizuno K, Hirai M, Kanazawa I, Nakagome Y, Tokunaga K and Toda T. . 1997 Genomics 40: 284–293.
Miyao N, Tsai YC, Lerner SP, Olumi AF, Spruck CH, Gonzalezzulueta M, Nichols PW, Skinner DG and Jones PA. . 1993 Cancer Res. 53: 4066–4070.
Nobori T, Miura K, Lois A, Takabayashi K and Carson DA. . 1994 Nature 368: 753–756.
Northrup H, Greenspan DS, Au KS and Blanton SH. . 1994 Ann. Hum. Genet. 58: 229–230.
Olopade OI, Jenkins RB, Ransom DT, Malik K, Pomykala H, Nobori T, Cowan JM, Rowley JD and Diaz MO. . 1992 Cancer Res. 52: 2523–2529.
Orlow I, Lianes P, Lacombe L, Dalbagni G, Reuter VE and Cordon-Cardo C. . 1994 Cancer Res. 54: 2848–2851.
Ozelius LJ, Hewett J, Kramer P, Bressman SB, Shalish C, De Leon D, Rutter M, Risch N, Brin MF, Markova ED, Limborska SA, Ivanova-Smolenskaya IA, McCormick MK, Fahn S, Buckler AJ, Gusella JF and Breakefield XO. . 1997 Genome Res. 7: 483–494.
Pericak-Vance MA, Bale AE, Haines JL, Kwiatkowski DJ, Pilz A, Slaugenhaupt S, White JA, Edwards JH, Marchuk D, Olopade OI, Attwood J and Povey S. . 1995 Ann. Hum. Genet. 59: 347–365.
Povey S, Smith M, Haines J, Kwiatkowski D, Fountain J, Bale A, Abbott C, Jackson I, Lawrie M and Hulten M. . 1992 Ann. Hum. Genet. 56: 167–182.
Povey S, Armour J, Farndon P, Haines JL, Knowles M, Olopade F, Pilz A and White JA. . 1994 Ann. Hum. Genet. 58: 177–200.
Povey S, Attwood J, Chadwick B, Frezal J, Haines JL, Knowles M, Kwiatkowski DJ, Olopade OI, Slaugenhaupt S, Spurr NK, Smith M, Steel K, White JA and Pericak-Vance MA. . 1997 Ann. Hum. Genet. 61: 183–206.
Rousseau F, Réhel R, Rouillard P, DeGranpré P and Khandjian EW. . 1994 Human Mutation 4: 51–54.
Ruppert JM, Tokino K and Sidransky D. . 1993 Cancer Res. 53: 5093–5095.
Shapiro GI and Rollins BJ. . 1996 Biochim. Biophys. Acta. 1242: 165–169.
Simoneau AR, Spruck CH III, Gonzalez-Zulueta M, Gonzalgo ML, Chan MF, Tsai YC, Dean M, Steven K, Horn T and Jones PA. . 1996 Cancer Res. 56: 5039–5043.
Stadler WM, Sherman J, Bohlander SK, Roulston D, Dreyling M, Rukstalis D and Olopade OI. . 1994 Cancer Res. 54: 2060–2063.
Tanaka M, Mullauer L, Ogiso Y, Fujita H, Moriya S, Furuuchi K, Harabayashi T, Shinohara N, Koyanagi T and Kuzumaki N. . 1995 Cancer Res. 55: 3228–3232.
Van Slegtenhorst M, De Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, Van den Ouweland A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M and Ravine D. . 1997 Science 277: 805–808.
Van Tilborg AAG, Hekman ACP, Vissers KJ, van der Kwast TH and Zwarthoff EC. . 1998 Int. J. Cancer 75: 9–14.
Zhang L, Cui X, Schmitt K, Hubert R, Navidi W and Arnheim N. . 1992 Proc. Natl. Acad. Sci. USA 89: 5847–5851.
Acknowledgements
This work was supported by the National Cancer Institute of USA, grant #CA47526. FR is a MRC scientist.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Simoneau, M., Aboulkassim, T., LaRue, H. et al. Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene 18, 157–163 (1999). https://doi.org/10.1038/sj.onc.1202277
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202277
Keywords
This article is cited by
-
An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells
Molecular Cancer (2011)
-
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
Cancer and Metastasis Reviews (2009)
-
Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: Pathological significance in early- and late-onset breast carcinoma
Molecular Cancer (2008)
-
Management of patients with upper urinary tract transitional cell carcinoma
Nature Clinical Practice Urology (2007)
-
Allelic Loss at Drosophila Patched Gene Is Highly Prevalent in Basal and Squamous Cell Carcinomas of the Skin
Journal of Investigative Dermatology (2006)